Market News & Trends
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study
Biogen Inc. recently announced the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene therapy…
Hovione Technology Completes Pilot-Scale Blister Manufacturing for the Papillon DPI
Hovione Technology recently announced it has completed pilot-scale blister manufacturing and filling for its new reusable blister-based dry powder inhaler, the Papillon DPI. Papillon targets…
Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies
Costas, Inc. DBA/Atlas Nanotech, (the Company) is currently in discussions to license their proprietary nanotechnology vitamin a (retinol) based crystalline eye drops known under the…
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals
CURE Pharmaceutical recently announced it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and…
PromoCell Now Offers In Vitro Disease Models That Could Lead to New Therapies
PromoCell now offers cell disease models covering a wide range of diseases, including diabetes type 1 and 2, respiratory diseases, such as COPD and asthma,…
New Study From Tufts Center for the Study of Drug Development Establishes Benchmarks
While more than 90% of all contract vendor assessments conducted by drug sponsors ultimately lead to vendors being qualified to provide services, large sponsors have…
Centogene Signs Collaboration Agreement With Pfizer
CENTOGENE recently announced a new data access and collaboration agreement with Pfizer Inc. The agreement grants Pfizer access to CENTOGENE’s data repository, which may be…
Aravive & AstraZeneca Announce Initiation of Randomized Phase 1/2 Study
Aravive, Inc. and AstraZeneca recently announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL inhibitor, in combination with durvalumab, a PD-L1 inhibitor,…
NervGen Pharma Expands Platform Into Alzheimer's Disease
NervGen Pharma Corp. recently announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis,…
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials
Menlo Therapeutics Inc. recently announced it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once-daily…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….